Catalyst Pharmaceuticals (CPRX) Net Cash Flow (2010 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Net Cash Flow came in at $46.7 million in Q1 2026, down 26.01% YoY from $63.1 million in Q1 2025, and up 142.17% on a QoQ basis from $19.3 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Net Cash Flow (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 17 years of Net Cash Flow data on file, last reported at $46.7 million in Q1 2026.
- Quarterly Net Cash Flow fell 26.01% year-over-year to $46.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $175.2 million (down 35.17% YoY) and the FY2025 annual result came in at $191.6 million, down 49.56% from the prior year.
- Net Cash Flow improved to $46.7 million in Q1 2026, from $19.3 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $172.8 million in Q1 2024 to a low of -$150.1 million in Q1 2023.
- A 5-year average of $33.8 million and a median of $42.3 million in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow tumbled 2267.58% — and 2024, when it surged 351.38%.
- Tracing CPRX's Net Cash Flow over 5 years: stood at $42.3 million in 2022, then sank by 60.63% to $16.7 million in 2023, then surged by 351.38% to $75.2 million in 2024, then slumped by 74.37% to $19.3 million in 2025, then surged by 142.17% to $46.7 million in 2026.
- The last three Net Cash Flow figures came in at $46.7 million (Q1 2026), $19.3 million (Q4 2025), and $37.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 46.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.69 Mn |
| Mar 31, 2026 | 46.69 Mn |
| Dec 31, 2025 | 19.28 Mn |
| Dec 31, 2025 | 19.28 Mn |
| Sep 30, 2025 | 37.09 Mn |
| Sep 30, 2025 | 37.09 Mn |
| Jun 30, 2025 | 72.14 Mn |
| Jun 30, 2025 | 72.14 Mn |
| Mar 31, 2025 | 63.10 Mn |
| Mar 31, 2025 | 63.10 Mn |
| Dec 31, 2024 | 75.22 Mn |
| Dec 31, 2024 | 75.22 Mn |
| Sep 30, 2024 | 66.64 Mn |
| Sep 30, 2024 | 66.64 Mn |
| Jun 30, 2024 | 65.28 Mn |
| Jun 30, 2024 | 65.28 Mn |
| Mar 31, 2024 | 172.78 Mn |
| Mar 31, 2024 | 172.78 Mn |
| Dec 31, 2023 | 16.67 Mn |
| Dec 31, 2023 | 16.67 Mn |